SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-24-000302
Filing Date
2024-01-03
Accepted
2024-01-03 18:24:30
Documents
3
Period of Report
2023-12-29

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1704324252.html 4  
1 FORM 4 wk-form4_1704324252.xml 4 3185
2 EX-24 powerofattorney_sharpx65.htm EX-24 3649
3 powerofattorney_sharpx65001.jpg GRAPHIC 181654
  Complete submission text file 0001628280-24-000302.txt   258564
Mailing Address C/O ULTRAGENYX PHARMACEUTICAL INC. 60 LEVERONI COURT NOVATO CA 94949
Business Address
Sharp Shalini (Reporting) CIK: 0001377202 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-35921 | Film No.: 24508811

Mailing Address 3545 CRAY COURT SAN DIEGO CA 92121
Business Address 3545 CRAY COURT SAN DIEGO CA 92121 858-332-3410
Mirati Therapeutics, Inc. (Issuer) CIK: 0001576263 (see all company filings)

IRS No.: 462693615 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)